NRG Oncology
Hospitals & Physicians Clinics · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1600 John F Kennedy Blvd Ste 1020, Phila...Phone Number
(267) 519-6630Website
www.nrgoncology.orgRevenue
$25.3 MillionIndustry
About NRG Oncology
NRG Oncology Org Chart
Is NRG Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if NRG Oncology has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if NRG Oncology had a recent Job posting/layoffs
NRG Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at NRG Oncology
Funding: Get notified immidiatlly once NRG Oncology has new funding data
Product Launch: Get notified when NRG Oncology launches new products
Check out if NRG Oncology is spiking on competitors!
Earning: See what the market has to say on NRG Oncology recently announced quarterly report
Recommended Actions
Find VP level buyers at NRG Oncology
Find 2 more new buyers
Compare Similar Companies to NRG Oncology
Compare insights from companies similar to NRG Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NRG Oncology
Company Profile Activity
Activity Insights
NRG Oncology is experiencing very low activity levels compared to other companies in the Hospitals & Physicians Clinics sector.
What does this means?
NRG Oncology is drawing exceptional interest within the Hospitals & Physicians Clinics industry, suggesting notable developments or strong market momentum, learn more about NRG Oncology.
NRG Oncology Tech Stack
A closer look at the technologies used by NRG Oncology
Most Recent Scoops
NRG Oncology News & Media
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) at six years for patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer. These results were presented todaThe Caris Precision Oncology Alliance Welcomes NRG Oncology
NRG Oncology joins Caris' extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine IRVING, Texas, Aug. 14, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation TechBio...Pieces Partners with NRG Oncology to Accelerate Identification of Patients for Clinical Trial on Colorectal Cancer Prevention
NRG'S FORTE study will leverage Pieces' AI and Natural Language Processing technologies to modernize the clinical trial process by automating the search for eligible patients DALLAS, June 7, 2022 /PRNewswire/ -- Pieces, a healthcare AI company, has been chosen as the technology partner...Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Top Hospitals & Physicians Clinics Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NRG Oncology
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer.... Read More